Buried Techniques To LY294002

In addition to this, bortezomib has demonstrated additive/synergistic activity in vitro and in mice when combined in a schedule-dependent manner with cyclophosphamide (O��Connor et?al, 2004), doxorubicin (Goy et?al, 2004), vincristine (Goy et?al, 2004), dexamethasone (Cloos et?al, 2004), cytarabine (Attar et?al, 2004; Weigert et?al, 2007), and rituximab (Smolewski et?al, 2006), all of which http://www.selleck.cn/products/wortmannin.html are components of the previously reported combination chemoimmunotherapy regimen comprising R Hyper-CVAD alternating with R-MA (Romaguera et?al, 2005). Combination data from bortezomib and the drugs present in R Hyper-CVAD (��part A��) have shown a manageable toxicity profile, with neurotoxicity being an important dose-limiting non-haematological toxicity (Kahl et?al, 2009). However, there is very little data on the combination of bortezomib with methotrexate and cytarabine. One potential concern is regarding lung damage. Data from studies in Japan, where patients with multiple myeloma received single agent bortezomib, showed that lung injury occurred when bortezomib was given at a dose and schedule similar to that in the proposed study (Miyakoshi et?al, 2006). This phenomenon might relate to genetic predisposition (Gotoh et?al, 2006) in the Japanese population. However, an African American patient with multiple myeloma http://www.selleckchem.com/products/LY294002.html has also been reported to suffer lung damage, which was presumably drug-related, after receiving bortezomib (Ohri & Arena, 2006). The current study investigated the potential clinical toxicity of bortezomib when combined with methotrexate and, particularly because of concerns from the drug manufacturer regarding lung toxicity, with the very high doses of cytarabine administered in the regimen. Patients with newly diagnosed aggressive MCL (nodular and diffuse histologies or blastoid cytology) were eligible after signing an informed consent form for a http://www.selleckchem.com/products/CHIR-99021.html Phase I trial approved by the Institutional Review Boards (IRBs) of both the University of Texas M. D. Anderson Cancer Center and the John Theurer Cancer Center at Hackensack University Medical Center, NJ, USA. Additional patient eligibility criteria included: between 18?years and 79?years of age, good Eastern Cooperative Oncology Group (ECOG) performance status (score of 2 or less) (Oken et?al, 1982), and adequate organ function, defined as cardiac ejection fraction ��50%, normal serum bilirubin level, and serum creatinine